|
|
|
|
|
Highlights from the 2023 American Urological Association Annual Meeting |
|
|
|
|
|
|
| State-of-the-Art Lecture: Histologic Subtypes in Renal Cell Carcinoma: Comparing and Contrasting Different Treatment Pathways/Options
|
| Brian Shuch, MD
|
| Brian Shuch gave a State-of-the-Art Lecture on the Histologic Subtypes of Renal Cell Carcinoma (RCC), and the impact that has on treatment pathways and options. Dr. Shuch notes that as Urologists, and specifically those with an expertise in kidney cancer, we should employ the tools we have in the right way.
|
|
|
|
|
|
| Panel Discussion: Small Renal Mass Management
|
| Antonio Finelli, MD, Jodi Maranchie, MD, and Monish Aron, MD
|
| During a panel on the management of small renal masses moderated by Stuart Wolf, Antonio Finelli discussed active surveillance, Jodi Maranchie discussed ablation, and Monish Aron discussed partial nephrectomy.
|
|
|
|
|
|
| Crossfire: Controversies in Urology: Thermal Ablation Versus Partial Nephrectomy for a 3 Cm Renal Mass in a 49 Year Old Male
|
| Ithaar Derweesh, MD, Jeffrey Cadeddu, MD, Alexander Kutikov, MD, FACS, and Robert Uzzo, MD, MBA, FACS
|
| Ultimately, the choice between partial nephrectomy or thermal ablation should be made in consultation with a qualified medical professional. When asked by Dr. Ball, from the National Cancer Institute, whether they perform partial nephrectomy or thermal ablation, all panelists admitted to incorporating both procedures in their clinical practice. The jury is still out on which approach is definitively better, as both have their own benefits and drawbacks.
|
|
|
|
|
|
|
|
| Real-world Survival Outcomes Associated With Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Papillary Renal Cell Carcinoma
|
| Carlos Riveros, MD,
|
| Carlos Riveros and his colleagues sought to describe real-world utilization trends of targeted therapy, immunotherapy, and immunotherapy + targeted therapy and their impact on overall survival in the setting of metastatic papillary RCC with or without cytoreductive nephrectomy.
|
|
|
|
|
|
| Generalizability of the MK-6482-004 Trial to Real-World VHL Patients: Results From a Prospective Surveillance Study |
| Federico Belladelli, MD |
| Despite the enthusiasm generated by the MK-6482-004 trial, the findings of the study appear applicable to a small proportion of real world VHL patients. Larger studies, focusing also on extra-renal VHL lesions are required to better define the role of MK-6482 for the treatment of VHL patients. |
|
|
|
|
|
|
|
|
|
|
| Partial versus Radical Nephrectomy for Complex Renal Mass: Multicenter Comparative Analysis of Functional Outcomes (ROSULA Collaborative Group)
|
| Clara Cerrato, MD
|
| Clara Cerrato discussed the impact of surgical modality on functional outcomes for the treatment of patients with complex renal mass. Although partial nephrectomy remains an accepted method of treatment for exophytic renal mass, its oncological efficiency in the utilization for CRM remains highly controversial.
|
|
|
|
|
|
| Complete Pathological Response in Patients Undergoing Nephrectomy for RCC Following Immune Checkpoint Inhibitor Therapy: A Multicenter Study
|
| Alireza Ghoreifi, MD
|
| In this cohort, 9% of patients who underwent nephrectomy following immune checkpoint inhibitors for advanced RCC showed complete pathological response in nephrectomy specimen. These patients demonstrated more favorable overall and progression-free survivals compared to those with residual tumor in the final specimen.
|
|
|
|
|
|
| Assessment of Surgical Complications in Patients with Metastatic Clear Cell RCC Receiving Perioperative Cabozantinib and Nivolumab on Cyto-KIK Clinical Trial
|
| Eric Singer, MD, MS, FACS, FASCO,
|
| Eric Singer discussed the assessment of surgical complications in patients with metastatic clear cell RCC receiving perioperative cabozantinib and nivolumab in the Cyto-KIK clinical trial. In the era of interferon-based therapy, radical nephrectomy improved survival in patients with metastatic RCC and became the standard of care.
|
|
|
|
|
|
| Virtual Renal Mass Biopsy: Predicting Renal Tumor Histology on Abdominal CT Images using Machine Learning
|
| Abhinav Khanna, MD
|
| Abhinav Khanna explored the association between advancing technology and renal tumors. Specifically, Khanna et. al looked to use a machine learning mechanism to diagnose benign vs malignant renal tumors. Dr. Khanna stresses in his presentation that 1 out of 3 partial nephrectomies are unnecessary. Therefore, finding alternative and more efficient ways to distinguish malignant vs nonmalignant is of great importance for patients who may be able to avoid invasive surgery if ultimately successful.
|
|
|
|
|
|
|
|
|
|
|
| First Analysis of the Safety and Efficacy of UGN-101 in the Treatment of Ureteral Tumors
|
| Joseph Jacob, MD, MCR
|
| UGN-101 appears to be equally safe and efficacious in treating low grade urothelial carcinoma of the ureter as compared to renal pelvic tumors. This data warrants further study of the use of UGN-101 for the treatment of low grade urothelial carcinoma of the ureter.
|
|
|
|
|
|
|
Imaging/Radiology: Uroradiology I
|
|
| Developing an Artificial Intelligence Model to Predict Differential Renal Function using Contrast-Enhanced CT Scans |
| Daniel Salevitz, MD |
| Daniel Salevitz discusses the use of an artificial intelligence model to evaluate differential kidney function. Specifically, his team sought to do so with automated methods of assessing contrast enhanced computed tomography in tandem with machine and deep learning algorithms, without the use of nuclear medical imaging. |
|
|
|
|
|
|
|
| Antimicrobial and Antibiofilm Properties of Chitosan: An Ex-Vivo Study on Kidney Stones |
| Grace H. Holton |
| The team led by Grace Holton at the Department of Urology in Stanford School of Medicine hypothesized that the inclusion of Chitosan, a chemical agent renowned for its ability to minimize microbiome and biofilm formation, could potentially eliminate uropathogens and bacterial biofilms commonly linked to kidney stones. Grace exclaimed that the agent chitosan has the potential to inhibit the growth of multiple gram negative and gram-positive pathogens, identified through in vitro studies. |
|
|
|
|
|
| Machine Learning Model to Predict Likelihood of Spontaneous Ureteral Stone Passage
|
| Katherine Fischer, MD
|
| Katherine Fischer presented on the development of a machine learning model for spontaneous ureteral stone passage. Dr. Fischer and her team are attempting to overcome the hurdle that prior studies have had difficulty efficiently defining specific factors that predict the likelihood of spontaneous passage.
|
|
|
|
|
|
| Follow-up 24-Hour Urine Studies During and Post-COVID-19 Pandemic |
| Pankti Kothari, MD |
| Pankti Kothari highlighting changes in urine composition for patients during the COVID-19 pandemic. Due to changes in the general population’s dietary and lifestyle habits, Dr. Kothari and her team sought to investigate how such changes can impact the urinary environment of patients and especially in relation to kidney stone formation. |
|
|
|
|
|
|
